Archive for Dr. John Zebala

Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor:  Zebala; John A. (Sammamish, WA) Abstract:  There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently […]

Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, […]

Syntrix Wins U.S. Patent 8,981,106: Pyrimidinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Syntrix Wins U.S. Patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide […]

Syntrix Publication in Journal of Medicinal Chemistry

Congratulations to Syntrix scientists on their latest publication, which appeared in the ACS Journal of Medicinal Chemistry.  Abstract: The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis.  In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2).  […]

Syntrix Wins U.S. Patent 8,748,623: Pyridinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Dr. Zebala Invited to Speak at the 2011-2012 David Rogers Health Policy Colloquium at the Weill Cornell Medical College

Dr. John Zebala, President and CEO of Syntrix Biosystems and alumnus of the Weill Cornell Medical College was an invited speaker at the 2011-2012 David E. Rogers Health Policy Colloquium. Dr. Zebala shared his experience with the current business and regulatory challenges facing early-stage drug development. Learn more about the life of David E. Rogers. 

New Syntrix Publication: Synthesis and evaluation of phosphopeptides containing iminodiacetate groups as binding ligands of the Src SH2 domain

Congratulations to Syntrix scientists and their collaborators at the University of Rhode Island on their latest publication, which appeared in the journal Bioorganic Chemistry. Link to paper.  

New Syntrix Publication in Nucleic Acids Research

Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Nucleic Acids Research. Abstract excerpts: We describe snap-to-it probes, a novel probe technology to enhance the hybridization specificity of natural and unnatural nucleic acid oligomers using a simple and readily introduced structural motif. Snap-to-it probes were prepared from peptide nucleic acid (PNA) oligomers by modifying each […]

Dr. John Zebala on UW TV: Lessons From A Biotech Entrepreneur

Dr. John Zebala, CEO of Syntrix Biosystems gives an overview of the elements necessary to forming an early stage biotechnology company, including conventional and alternative sources of financing, strategies for developing a strong intellectual property portfolio and other first-hand lessons learned during the formation process of a biotechnology business. Watch the broadcast.